Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and heteroGISA strains

Biochimica et Biophysica Acta - General Subjects

Volumn 1726, Issue 3, 2005, Pages 326-327

  Wootton, M ^a   Macgowan, A P ^b   Walsh, T R ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NONE

Author keywords

Clinical isolate; Gene expression; Glycopeptide intermediate resistance; Mechanism of resistance; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; GLYCOPEPTIDE; VANCOMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

BACTERIAL PROTEINS; GENE EXPRESSION; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS;

EID: 27944489962     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2005.09.002     Document Type: Article

References (8)

1. H. Maki, N. McCallum, M. Bischoff, A. Wada, and B. Berger-Bächi tcaA inactivation increases glycopeptide resistance in Staphylococcus aureus Antimicrob. Agents Chemother. 48 2004 1953 1959
2. A. Ruzin, A. Severin, S.L. Moghazeh, J. Etienne, P.A. Bradford, S.J. Projan, and D.M. Shlaes Inactivation of mpr affects vancomycin susceptibility in Staphylococcus aureus Biochim. Biophys. Acta 1621 2003 117 121
3. H. Nishi, H. Komatsuzawa, T. Fujiwara, N. McCallum, and M. Sugai Reduced content of lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin and antimicrobial peptides in Staphylococcus aureus Antimicrob. Agents Chemother. 48 2004 4800 4807
4. A. Peschel, R.W. Jack, M. Otto, L.V. Collins, P. Staubitz, G. Nicholson, H. Kalbacher, W.F. Niewenhuizen, G. Jung, A. Tarkowski, K.P.M. van Kessel, and J.A.G. van Strijp Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine J. Exp. Med. 193 2001 1067 1076
5. M.C. Ploy, C. Grélaud, C. Martin, L. de Lumley, and F. Denis First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital Lancet 351 1998 1212
6. K. Sieradski, R.B. Roberts, S.W. Haber, and A. Tomasz The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection N. Engl. J. Med. 340 1999 517 523
7. K. Hiramatsu, H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F.C. Tenover Methicillin resistant Staphylococcus aureus strain with reduced vancomycin susceptibility J. Antimicrob. Chemother. 40 1997 135 146
8. M. Kuroda, H. Kuroda, T. Oshima, F. Takeuchi, H. Mori, and K. Hiramatsu Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus Mol. Microbiol. 49 2003 807 821